The Relationship Between the Endoscopic Healing Index, Fecal Calprotectin, and Magnetic Resonance Enterography in Crohn's Disease.
Journal
Journal of clinical gastroenterology
ISSN: 1539-2031
Titre abrégé: J Clin Gastroenterol
Pays: United States
ID NLM: 7910017
Informations de publication
Date de publication:
21 Aug 2023
21 Aug 2023
Historique:
received:
19
01
2023
accepted:
14
07
2023
medline:
30
8
2023
pubmed:
30
8
2023
entrez:
30
8
2023
Statut:
aheadofprint
Résumé
The serum-based endoscopic healing index (EHI) test identifies endoscopic Crohn's disease (CD) activity. Data are lacking on the relationship between EHI with other endpoints. We assessed the relationship between EHI and the simplified Magnetic Resonance Index of Activity. Data were prospectively collected on patients with CD with either an EHI or fecal calprotectin (FCAL) within 90 days of magnetic resonance enterography (MRE). Diagnostic accuracy was assessed using area under the receiver operator characteristics. Proportions with any, severe, and terminal ileum MR inflammation were compared above/below identified thresholds for both EHI and FCAL. A total of 241 MREs paired to either EHI or FCAL from 155 patients were included. Both EHI and FCAL had similar accuracy to diagnose inflammation (area under the receiver operator characteristics: EHI: 0.635 to 0.651, FCAL: 0.680 to 0.708). Optimal EHI values were 42 and 26 for inflammation on MRE and endoscopy, respectively. Patients with EHI ≥42 (100% vs. 63%, P=0.002), FCAL >50 µg/g (87% vs. 64%, P<0.001) and FCAL >250 µg/g (90% vs. 75%, P=0.02) had higher rates of simplified Magnetic Resonance Index of Activity ≥1 compared with lower values. EHI differentiated ileitis numerically more than FCAL (delta: 24% to 25% vs. 11% to 21%). Patients with FCAL ≥50 µg/g had higher rates of severe inflammation compared with FCAL <50 µg/g (75% vs. 47%, P<0.001), whereas smaller differentiation existed for EHI threshold of 42 (63% vs. 49%, P=0.35). Both EHI and FCAL were specific in their confirmation of inflammation and disease activity on MRE in patients with CD. However, MRE-detected inflammation was frequently present in the presence of low EHI and FCAL in similar proportions.
Identifiants
pubmed: 37646564
doi: 10.1097/MCG.0000000000001904
pii: 00004836-990000000-00195
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Cosnes J, Gowerrousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794.
Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12:113.
Naganuma M, Hosoe N, Kanai T, et al. Recent trends in diagnostic techniques for inflammatory bowel disease. Korean J Intern Med. 2015;30:271–278.
Rozendorn N, Klang E, Lahat A, et al. Prediction of patency capsule retention in known Crohn’s disease patients by using magnetic resonance imaging. Gastrointest Endosc. 2016;83:182–187.
Ahmad R, Ajlan AM, Eskander AA, et al. Magnetic resonance imaging in the management of Crohn’s disease: a systematic review and meta-analysis. Insights Imaging. 2021;12:1–8.
Sandborn WJ, Abreu MT, Dubinsky MC. A noninvasive method to assess mucosal healing in patients with Crohn’s disease. Gastroenterol Hepatol (NY). 2018;14:1–12.
Ordás I, Rimola J, Alfaro I, et al. Development and validation of a simplified magnetic resonance index of activity for Crohn’s disease. Gastroenterology. 2019;157:432–439.
Capozzi N, Ordás I, Fernandez-Clotet A, et al. Validation of the simplified magnetic resonance index of activity without gadolinium-enhanced sequences for Crohn’s disease. J Crohns Colitis. 2020;14:1074–1081.
Ma C, Battat R, Khanna R, et al. What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn’s disease activity? Best Pract Res Clin Gastroenterol. 2019;38-39:101602.
Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:802–819.
Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9:421–427.
Bjarnason I. The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (NY). 2017;13:53–56.
D’Haens G, Kelly O, Battat R, et al. Development and validation of a test to monitor endoscopic activity in patients with Crohn’s disease based on serum levels of proteins. Gastroenterology. 2020;158:515–526.
Limketkai BN, Singh S, Jairath V, et al. US practice patterns and impact of monitoring for mucosal inflammation after biologic initiation in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25:1828–1837.
Roseira J, Ventosa AR, de Sousa HT, et al. The new simplified MARIA score applies beyond clinical trials: a suitable clinical practice tool for Crohn’s disease that parallels a simple endoscopic index and fecal calprotectin. United Eur Gastroenterol J. 2020;8:1208.
Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.
Khanna R, Zou G, D’Haens G, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn’s disease activity. Aliment Pharmacol Ther. 2015;41:77–86.
Danese S, Sandborn WJ, Colombel JF, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. Gastroenterology. 2019;157:1007–1018.
Reinisch W, Colombel JF, D’Haens G, et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: results from the EXTEND Trial. J Crohns Colitis. 2017;11:425–434.
Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.
Battat R. Serum monitoring of recurrence in post-operative Crohn’s disease: have we arrived? J Crohn’s Colitis. 2022;16:1795–1796.
Kopylov U, Yung DE, Engel T, et al. Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn’s disease: systematic review and meta-analysis. Dig Liver Dis. 2017;49:854–863.
Hamilton AL, De Cruz P, Wright EK, et al. Non-invasive serological monitoring for Crohn’s disease postoperative recurrence. J Crohn’s Colitis. 2022;16:1–11.
Makanyanga JC, Pendsé D, Dikaios N, et al. Evaluation of Crohn’s disease activity: Initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol. 2014;24:277–287.
Jones GR, Fascì-Spurio F, Kennedy NA, et al. Faecal calprotectin and magnetic resonance enterography in ileal Crohn’s disease: correlations between disease activity and long-term follow-up. J Crohns Colitis. 2019;13:442–450.
Ye L, Chen W, Chen BQ, et al. Levels of faecal calprotectin and magnetic resonance enterocolonography correlate with severity of small bowel Crohn’s disease: a retrospective cohort study. Sci Reports. 2017;7:1–8.
Somwaru AS, Khanijow V, Katabathina VS. Magnetic resonance enterography, colonoscopy, and fecal calprotectin correlate in colonic Crohn’s disease. BMC Gastroenterol. 2019;19:1–9.
Cerrillo E, Beltrán B, Pous S, et al. Fecal calprotectin in ileal Crohn’s disease: relationship with magnetic resonance enterography and a pathology score. Inflamm Bowel Dis. 2015;21:1572–1579.
Rozendorn N, Amitai MM, Eliakim RA, et al. A review of magnetic resonance enterography-based indices for quantification of Crohn’s disease inflammation. Therap Adv Gastroenterol. 2018;11:1756284818765956.
Buisson A, Mak WY, Andersen MJ, et al. Fecal calprotectin is highly effective to detect endoscopic ulcerations in Crohn’s disease regardless of disease location. Inflamm Bowel Dis. 2021;27:1008.
Rokkas T, Portincasa P, Koutroubakis IE. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis. 2018;27:299–306.